TOKYO and CAMBRIDGE, United Kingdom, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, has been notified by its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX) that the U.S. Food and Drug Administration (FDA) Investigational New…
Mon, 08 Aug 2022 05:06:00 GMT Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation ...
Thu, 04 Aug 2022 17:24:00 GMT Q2 2022 Earnings Conference Call August 04, 2022 04:30 PM ET Company Participants Todd Tushla - Vice President of Investor Relations ...
Thu, 04 Aug 2022 13:03:00 GMT Pipeline prioritizes tau antibody for Alzheimer’s disease and gene therapies for GBA1 Parkinson’s disease and SOD1 ALS, each program employing efficient paths to human proof of biology Targeting ...
Tue, 02 Aug 2022 08:00:00 GMT Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year studyAs previously reported, numerical differences favoring crenezumab over placebo were confirmed ...
